Correction to “The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of RSV-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age”

IF 4.2 4区医学 Q1 INFECTIOUS DISEASES

Influenza and Other Respiratory Viruses Pub Date : 2025-02-23 DOI:10.1111/irv.70088

{"title":"Correction to “The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of RSV-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age”","authors":"","doi":"10.1111/irv.70088","DOIUrl":null,"url":null,"abstract":"\n Curran, D, Matthews, S, Cabrera, ES, et al., The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of Respiratory Syncytial Virus-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age. Influenza Other Respi Viruses. 2024; 18(2):e13236.\n In the article, there were errors in the affiliations of Laura Helman and John H. Powers III. Their correct affiliations are shown below.Desmond Curran 1 |Sean Matthews 2|Eliazar Sabater Cabrera 1 |Silvia Narejos Pérez 3|Lina Pérez Breva 4|Mika Rämet 5|Laura Helman 6|Dae Won Park 7|Tino F. Schwarz 8|Isabel Maria Galan Melendez 9|Axel Schaefer 10|Nathalie Roy 11|Brigitte Stephan 12|Daniel Molnar 1 |Lusine Kostanyan 1 |John H. Powers III 13|Veronica Hulstrøm 1|Members of the AReSVi-006 Study Group1GSK, Wavre, Belgium2 Freelance c/o GSK, Wavre, Belgium3 CAP Centelles, Barcelona, Spain4 Vaccine Research, FISABIO-Public Health, Valencia, Spain5 Finnish Vaccine Research, Tampere, Finland6 MOC Research, Mishawaka, Indiana, USA7 Korea University Ansan Hospital, Ansan, Republic of Korea8 Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Würzburg, Germany9 Hospital Universitario Fundacion Alcorcon, Madrid, Spain10 Medizentrum Essen Borbeck, Essen, Germany11 Medicor Research, Greater Sudbury, Canada12 SGS proDERM, Schenefeld, Germany13 Department of Clinical Medicine, George Washington University School of Medicine & Health Sciences, Washington, District of Columbia, USAWe apologize for this error.","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 2","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70088","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70088","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Curran, D, Matthews, S, Cabrera, ES, et al., The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of Respiratory Syncytial Virus-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age. Influenza Other Respi Viruses. 2024; 18(2):e13236.

In the article, there were errors in the affiliations of Laura Helman and John H. Powers III. Their correct affiliations are shown below.

¹GSK, Wavre, Belgium

² Freelance c/o GSK, Wavre, Belgium

³ CAP Centelles, Barcelona, Spain

⁴ Vaccine Research, FISABIO-Public Health, Valencia, Spain

⁵ Finnish Vaccine Research, Tampere, Finland

⁶ MOC Research, Mishawaka, Indiana, USA

⁷ Korea University Ansan Hospital, Ansan, Republic of Korea

⁸ Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Würzburg, Germany

⁹ Hospital Universitario Fundacion Alcorcon, Madrid, Spain

¹⁰ Medizentrum Essen Borbeck, Essen, Germany

¹¹ Medicor Research, Greater Sudbury, Canada

¹² SGS proDERM, Schenefeld, Germany

¹³ Department of Clinical Medicine, George Washington University School of Medicine & Health Sciences, Washington, District of Columbia, USA

We apologize for this error.

查看原文本刊更多论文

对“呼吸道合胞病毒预融合F蛋白疫苗减轻≥60岁成人突破性感染中rsv相关疾病的严重程度”的更正

Curran， D, Matthews， S, Cabrera， ES，等。呼吸道合胞病毒预融合F蛋白疫苗降低60岁以上成年人突破性感染呼吸道合胞病毒相关疾病的严重程度。流感和其他呼吸病毒。2024；18 (2): e13236。在这篇文章中，劳拉·赫尔曼和约翰·h·鲍尔斯三世的从属关系存在错误。它们的正确从属关系如下所示。Desmond Curran 1| Sean Matthews 2|Eliazar Sabater Cabrera 1| Silvia Narejos psamez 3|Lina psamez Breva 4|Mika Rämet 5|Laura Helman 6|Dae Won Park 7|Tino F. Schwarz 8|Isabel Maria Galan Melendez 9| |Nathalie Roy 11|Brigitte Stephan 12|Daniel Molnar 1| Lusine Kostanyan 1| John H. Powers 3 13|Veronica hulster øm 1| AReSVi-006研究小组成员1GSK， Wavre，比利时2自由职业c/o GSK， Wavre，比利时3 CAP Centelles，巴塞罗那4疫苗研究，fisabio -公共卫生，西班牙瓦伦西亚5芬兰坦佩雷芬兰疫苗研究所6美国印第安纳州米沙瓦卡MOC研究中心7韩国安山高丽大学安山医院8德国w rzburg Mitte Klinikum实验室医学研究所和疫苗接种中心9西班牙马德里大学阿尔科康基金会医院10德国埃森博尔贝克医学中心11加拿大大萨德伯里医学研究中心12德国舍恩菲尔德SGS proDERM临床医学系乔治华盛顿大学医学院；健康科学，华盛顿，哥伦比亚特区，美国。我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.